The UK National Appeals Panel Safely Extends Access to Liver Transplantation for Candidates Beyond Standard Listing Criteria.

Hakeem, AR.; Gupta, S.; Taylor, R.; Grammatikopoulos, T.; Masson, S.; Prasad, R.; Thorburn, D.; Menon, K.; Manas, D.; Aluvihare, V.

The UK National Appeals Panel Safely Extends Access to Liver Transplantation for Candidates Beyond Standard Listing Criteria.

All Authors

Hakeem, AR.

Gupta, S.

Taylor, R.

Grammatikopoulos, T.

Masson, S.

Prasad, R.

Thorburn, D.

Menon, K.

Manas, D.

Aluvihare, V.

LTHT Author

Prasad, Raj

LTHT Department

Abdominal Medicine & Surgery
Upper Gastrointestinal Surgery

Publication Date

2026

Item Type

Journal Article

Subject

HOSPITALISATION , LIVER TRANSPLANTATION , TREATMENT OUTCOME , UNITED KINGDOM , WAITING LISTS , RETROSPECTIVE STUDIES , ADULT , CHILD , TISSUE AND ORGAN PROCUREMENT , MEN , MIDDLE AGED , WOMEN , HEALTH SERVICES ACCESSIBILITY , PATIENT SELECTION , ADOLESCENT , AGED , LIVER DISEASES , CHILD, PRESCHOOL

Abstract

Liver transplantation (LT) is the definitive treatment for selected acute and chronic liver diseases, yet standard national listing criteria do not encompass all clinical situations. To address this, the United Kingdom (UK) established the National Appeals Panel (NAP) in 2011 to review exceptional cases, aiming to ensure equitable access while safeguarding allocation of scarce donor organs. We conducted a retrospective analysis of all appeals submitted to the NAP between 2011 and 2020. 149 appeals were received: 139 (93.3%) adults and 10 (6.7%) paediatric patients. Overall, 128 (85.9%) appeals were approved, 19 (12.8%) declined, and 2 (1.3%) withdrawn. Approval was more frequent for adult super-urgent than elective requests (92.9% vs. 79.5%). Of 118 approved adults, 95 (80.5%) underwent LT, while 23 (19.5%) did not, most often due to deterioration on the waiting list. Transplanted adults included 46.3% super-urgent cases, with 20% ventilated and 25.3% on renal replacement therapy, yet achieved excellent outcomes with 98% one-year and 90% five-year survival. All 10 paediatric appeals were approved, with one child dying on the list and nine transplanted. Declined appeals mainly involved older patients with malignant indications. This review highlights the NAP's role in expanding LT access while ensuring equity and governance.